Biotech Industry · uk
OMass Raises $310 Million to Advance Small-Molecule Drugs for Adrenal Diseases and Lupus
The new funding will support OMS1620 through Phase 2 development in congenital adrenal hyperplasia and enable another candidate for immune diseases to generate initial human data. Both programs are entering a stage that will test whether their drug designs can translate into patient benefit.
For hormonal imbalances and autoimmune diseases, identifying a biological target for intervention is only the starting point of drug development. On October 15, UK biotech company OMass Therapeutics announced the completion of a $310 million Series C financing, equivalent to approximately £230 million, to advance two small-molecule drug programs toward more concrete testing in humans: one targeting adrenal diseases and the other targeting lupus-related immune abnormalities.
The oversubscribed round was co-led by Bain Capital Life Sciences, Forbion and Novo Holdings, with participation from all existing investors. Goodwin, which served as legal adviser on the transaction, separately confirmed that the funding will support Phase 2 clinical development of lead candidate OMS1620 in congenital adrenal hyperplasia, as well as development in adrenocorticotropic hormone (ACTH)-dependent Cushing’s syndrome.
OMS1620 is a melanocortin 2 receptor (MC2 receptor) antagonist. According to announcements from OMass and Forbion, its design focuses on extending the time the drug remains bound to the receptor and maintaining activity when ACTH levels in the body are elevated. The company hopes this will allow patients with congenital adrenal hyperplasia to bring androgen levels into the normal range while using glucocorticoid doses close to physiological requirements. This is a development objective; the announcements did not provide patient efficacy data to substantiate it.
The two endocrine indications involve different hormonal imbalances. Congenital adrenal hyperplasia is a genetic condition present at birth, in which abnormal adrenal function may affect growth, fertility and stress responses. Cushing’s syndrome is associated with prolonged exposure to excessive cortisol. OMass is targeting the ACTH-dependent form, and its development scope should not be interpreted as covering all patients with Cushing’s syndrome.
Another portion of the funding will go toward an SLC15A4 inhibitor, with the goal of obtaining initial clinical data to explore its therapeutic potential in lupus and other diseases associated with excess interferon and pathogenic B-cell activation. This program remains at an early stage; the announcement disclosed no human trial results and did not specify participant numbers, doses or the timing of data readouts.
Background
OMass originated in Carol Robinson’s laboratory at the University of Oxford. Its OdyssION drug discovery platform combines native mass spectrometry, biochemistry and chemical design to study targets within their original molecular environments. Existing shareholder Syncona said the round brings the company’s total funding raised to approximately $475 million. Syncona itself committed $10.1 million and expects to hold a 16.1% equity stake once all committed funding for the round has been received.
The funding sets clear next steps for the two programs: OMS1620 must progress through Phase 2 development, while the SLC15A4 inhibitor must establish initial human evidence. The financing announcement has not yet provided sufficient data to assess efficacy, safety or advantages over existing treatments. Whether the drug can maintain its activity in a high-ACTH environment, and whether immune modulation can deliver an acceptable balance of benefits and risks, remain questions for subsequent clinical studies.